Novo Nordisk Faces a Double Squeeze: Lilly’s Record-Breaking Data and a High-Stakes Court Date
Eli Lilly has thrown down a fresh gauntlet in the GLP-1 arms race, unveiling late-stage data that shows…
Novo Nordisk Balances a $25M Ransom Demand and a High-Stakes FDA Decision as Shares Rebound
Novo Nordisk has clawed back more than a third of its value from March lows, yet the Danish…
Novo Nordisk Faces a High-Stakes Balancing Act: Wegovy Pill Approval vs. Escalating Cyber Threats
Novo Nordisk ended a week of stark contrasts with its shares stuck near EUR 38.90 — a modest…
Greenland Approvals and a $24 Million Cash Gap Test the Rally
European Lithium stock rallies 205% YTD, but merger with Critical Metals faces A$24M cash shortfall and exclusivity ban…
Oral Ozempic Hits Pharmacies as Earnings Test Investor Patience
Novo Nordisk launches oral Ozempic in the US amid Q1 earnings decline, Eli Lilly competition, and patent pressures.…